Home / Resource Library / Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

Results of a study investigating ibrutinib with rituximab for treatment of follicular lymphoma.